Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Last updated: September 13, 2023
Sponsor: Heron Therapeutics
Overall Status: Completed

Phase

2

Condition

Chronic Pain

Pain

Bunion

Treatment

HTX-011A

HTX-011B

Bupivacaine HCl

Clinical Study ID

NCT02762929
HTX-011-C2016-208
  • Ages > 18
  • All Genders

Study Summary

A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Be male or female 18 years of age or older
  2. Female subjects are eligible only if all of the following apply:
  3. Not pregnant (female subject of child bearing potential must have a negativeserum pregnancy test at screening and negative urine pregnancy test beforesurgery)
  4. Not lactating
  5. Not planning to become pregnant while participating in the study
  6. Be surgically sterile; or be at least two years post-menopausal; or have amonogamous partner who is surgically sterile; or be practicing double-barriercontraception; or practicing abstinence (must agree to use double-barriercontraception in the event of sexual activity); or using an insertable,injectable, transdermal, or combination oral contraceptive approved by the FDAfor greater than 2 months prior to screening visits and commits to the use of anacceptable form of birth control for the duration of the study and for 30 daysfrom completion of the study
  7. Male subjects must be surgically sterile (biologically or surgically) or commit to theuse of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication
  8. Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair,without collateral procedures, under regional anesthesia
  9. Subject has not had a contralateral bunionectomy in the non-study foot in the past 3months
  10. Have the ability and be willing to comply with the study procedures.
  11. Must be able to understand study procedures and give informed consent for the conductfor all study procedures, using an IRB approved consent form

Exclusion

Exclusion Criteria:

  1. Unwilling to sign informed consent or not willing or able to complete all studyprocedures
  2. Have a contraindication or be allergic to any medication to be used during the trialperiod
  3. Have clinically significant cardiac abnormalities that, in the opinion of theinvestigator, would pose a health risk to the subject
  4. Have American Society of Anesthesiologists (ASA) Physical Status classification systemcategory ≥4
  5. Have clinically significant renal or hepatic abnormalities: for example, AST or ALT > 3x ULN, creatinine > 2x ULN
  6. Have another pre-existing painful condition that may confound pain assessments
  7. Have another surgery planned within 30 days of procedure
  8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen
  9. Currently taking analgesics for a chronically painful condition, or has taken longacting opioids within 3 days of surgery, or taken any opioids within 24 hours ofscheduled surgery for this study
  10. Subjects with documented sleep apnea or are on home continuous positive airwaypressure (CPAP)
  11. Subjects who are receiving oxygen therapy at the time of screening
  12. Have participated in a clinical trial within 30 days of planned surgery

Study Design

Total Participants: 430
Treatment Group(s): 6
Primary Treatment: HTX-011A
Phase: 2
Study Start date:
May 01, 2016
Estimated Completion Date:
March 31, 2017

Study Description

This study includes multiple formulations for formulation selection of the fixed-combination product and for the factorial design assessment of the contribution of each component. HTX-011A is the second formulation studied (HTX-011-49). HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies. For the factorial design assessment, HTX-002, a bupivacaine-only formulation in the same HTX-011 proprietary polymer, and HTX-009, a meloxicam-only formulation in the same HTX-011 proprietary polymer, were evaluated.

Connect with a study center

  • Anaheim, California 92801
    United States

    Site Not Available

  • Bakersfield, California 93311
    United States

    Site Not Available

  • Pasadena, Maryland 21122
    United States

    Site Not Available

  • Houston, Texas 77027
    United States

    Site Not Available

  • San Antonio, Texas 78229
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.